Syndax Pharmaceuticals announced four abstracts on Revuforj (revumenib) accepted for presentation at ASCO 2026, including an oral presentation on favorable outcomes in 21 leukemia patients treated post-transplant. The data emphasize Revuforj's unique pharmacokinetics, allowing use with gastric acid reducers and low-fat meals. Ongoing pivotal trials combining Revuforj with chemotherapy in newly diagnosed acute leukemia will also be discussed, underscoring its potential to improve treatment options for certain genetic leukemia subtypes.
Auddia Inc. announced a 12-month partnership between its AI-driven Discovr Radio platform and Beatcave, Canada's leading independent music community. Discovr Radio becomes Beatcave's official membership partner, offering independent artists guarantee...
Heineken N.V. has repurchased a total of 3,192,296 shares under the second €750 million tranche of its €1.5 billion share buyback program, spending €219.6 million as of May 29, 2026. The shares were bought both on the exchange and from Heineken Holdi...
Uber, Autobrains, and NVIDIA announced plans to launch a robotaxi program in Munich using Autobrains’ AI and NVIDIA’s Level 4 autonomous driving platform, pending regulatory approval. This partnership aims to scale autonomous ride-hailing across mult...
Netcompany Group A/S is actively executing its share buyback programme initiated in February 2026, aiming to repurchase up to 3,250,000 shares or DKK 750 million to optimize its capital structure and fulfill share-based incentive obligations. From Ma...
The global smartphone market is projected to grow from $609.29 billion in 2026 to $739.23 billion by 2031, with a CAGR of 3.94%. Growth is fueled by increasing adoption of 5G devices, AI-powered features, premium upgrades, and innovations like foldab...
